Checkpoint Therapeutics confirms FDA approval of unloxcyt

Checkpoint Therapeutics (CKPT) announced that the U.S. FDA has approved unloxcyt for the treatment of adults with metastatic cutaneous squamous cell carcinoma or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Unloxcyt is the first and only programmed death ligand-1 blocking antibody to receive FDA marketing approval for this indication. The recommended commercial dosage of unloxcyt is 1,200 mg administered as an intravenous infusion over 60 minutes every three weeks.